Treatment of tardive akathisia

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Tardive akathisia (TA) is characterized by a subjective sense of motor restlessness associated with objective motor movements that occur in the setting of chronic therapy with dopamine receptor blocking agents (DBA). Acute akathisia typically occurs in the setting of initial therapy or with an increase in dose of DBA and is often quite responsive to lowering the dose or stopping the DBA or adding β-adrenergic blocking agents and benzodiazepines. By contrast, TA is often very difficult to treat and may emerge in the setting of DBA withdrawal. There are currently no FDA-approved therapies or significant randomized clinical trials looking at treatments for TA, but there are some published case series of potentially beneficial therapies. These medications include anticholinergics, β-adrenergic blocking agents, clonazepam, clonidine, dopamine agonists, and dopamine-depleting agents such as reserpine and tetrabenazine, pregabalin, mirtazapine, and zolpidem. A summary table of potential therapies is provided.

Original languageEnglish (US)
Title of host publicationCurrent Clinical Neurology
PublisherHumana Press Inc.
Pages297-299
Number of pages3
DOIs
StatePublished - Jan 1 2019

Publication series

NameCurrent Clinical Neurology
ISSN (Print)1559-0585

Fingerprint

Drug-Induced Akathisia
Dopamine Receptors
Psychomotor Agitation
Adrenergic Antagonists
Tetrabenazine
Therapeutics
Clonazepam
Dopamine Agents
Reserpine
Dopamine Agonists
Cholinergic Antagonists
Clonidine
Benzodiazepines
Randomized Controlled Trials

Keywords

  • Anticholinergics
  • Clonazepam
  • Clonidine
  • Pregabalin
  • Reserpine
  • Tardive akathisia
  • Tardive syndrome
  • Tetrabenazine
  • Zolpidem
  • β-Adrenergic blocking agents

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Morgan, J. C. (2019). Treatment of tardive akathisia. In Current Clinical Neurology (pp. 297-299). (Current Clinical Neurology). Humana Press Inc.. https://doi.org/10.1007/978-3-319-97897-0_67

Treatment of tardive akathisia. / Morgan, John Christopher.

Current Clinical Neurology. Humana Press Inc., 2019. p. 297-299 (Current Clinical Neurology).

Research output: Chapter in Book/Report/Conference proceedingChapter

Morgan, JC 2019, Treatment of tardive akathisia. in Current Clinical Neurology. Current Clinical Neurology, Humana Press Inc., pp. 297-299. https://doi.org/10.1007/978-3-319-97897-0_67
Morgan JC. Treatment of tardive akathisia. In Current Clinical Neurology. Humana Press Inc. 2019. p. 297-299. (Current Clinical Neurology). https://doi.org/10.1007/978-3-319-97897-0_67
Morgan, John Christopher. / Treatment of tardive akathisia. Current Clinical Neurology. Humana Press Inc., 2019. pp. 297-299 (Current Clinical Neurology).
@inbook{0d6832649af84722878954b9606c5651,
title = "Treatment of tardive akathisia",
abstract = "Tardive akathisia (TA) is characterized by a subjective sense of motor restlessness associated with objective motor movements that occur in the setting of chronic therapy with dopamine receptor blocking agents (DBA). Acute akathisia typically occurs in the setting of initial therapy or with an increase in dose of DBA and is often quite responsive to lowering the dose or stopping the DBA or adding β-adrenergic blocking agents and benzodiazepines. By contrast, TA is often very difficult to treat and may emerge in the setting of DBA withdrawal. There are currently no FDA-approved therapies or significant randomized clinical trials looking at treatments for TA, but there are some published case series of potentially beneficial therapies. These medications include anticholinergics, β-adrenergic blocking agents, clonazepam, clonidine, dopamine agonists, and dopamine-depleting agents such as reserpine and tetrabenazine, pregabalin, mirtazapine, and zolpidem. A summary table of potential therapies is provided.",
keywords = "Anticholinergics, Clonazepam, Clonidine, Pregabalin, Reserpine, Tardive akathisia, Tardive syndrome, Tetrabenazine, Zolpidem, β-Adrenergic blocking agents",
author = "Morgan, {John Christopher}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-3-319-97897-0_67",
language = "English (US)",
series = "Current Clinical Neurology",
publisher = "Humana Press Inc.",
pages = "297--299",
booktitle = "Current Clinical Neurology",

}

TY - CHAP

T1 - Treatment of tardive akathisia

AU - Morgan, John Christopher

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Tardive akathisia (TA) is characterized by a subjective sense of motor restlessness associated with objective motor movements that occur in the setting of chronic therapy with dopamine receptor blocking agents (DBA). Acute akathisia typically occurs in the setting of initial therapy or with an increase in dose of DBA and is often quite responsive to lowering the dose or stopping the DBA or adding β-adrenergic blocking agents and benzodiazepines. By contrast, TA is often very difficult to treat and may emerge in the setting of DBA withdrawal. There are currently no FDA-approved therapies or significant randomized clinical trials looking at treatments for TA, but there are some published case series of potentially beneficial therapies. These medications include anticholinergics, β-adrenergic blocking agents, clonazepam, clonidine, dopamine agonists, and dopamine-depleting agents such as reserpine and tetrabenazine, pregabalin, mirtazapine, and zolpidem. A summary table of potential therapies is provided.

AB - Tardive akathisia (TA) is characterized by a subjective sense of motor restlessness associated with objective motor movements that occur in the setting of chronic therapy with dopamine receptor blocking agents (DBA). Acute akathisia typically occurs in the setting of initial therapy or with an increase in dose of DBA and is often quite responsive to lowering the dose or stopping the DBA or adding β-adrenergic blocking agents and benzodiazepines. By contrast, TA is often very difficult to treat and may emerge in the setting of DBA withdrawal. There are currently no FDA-approved therapies or significant randomized clinical trials looking at treatments for TA, but there are some published case series of potentially beneficial therapies. These medications include anticholinergics, β-adrenergic blocking agents, clonazepam, clonidine, dopamine agonists, and dopamine-depleting agents such as reserpine and tetrabenazine, pregabalin, mirtazapine, and zolpidem. A summary table of potential therapies is provided.

KW - Anticholinergics

KW - Clonazepam

KW - Clonidine

KW - Pregabalin

KW - Reserpine

KW - Tardive akathisia

KW - Tardive syndrome

KW - Tetrabenazine

KW - Zolpidem

KW - β-Adrenergic blocking agents

UR - http://www.scopus.com/inward/record.url?scp=85066914968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066914968&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-97897-0_67

DO - 10.1007/978-3-319-97897-0_67

M3 - Chapter

T3 - Current Clinical Neurology

SP - 297

EP - 299

BT - Current Clinical Neurology

PB - Humana Press Inc.

ER -